Article info
PDFCommentary
Patient-reported outcome measures should not be the primary outcome in glaucoma clinical trials of disease modification
- Correspondence to Professor Andrew Ian McNaught, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham GL53 7AN, Gloucestershire, UK; andrew.mcnaught{at}nhs.net
Citation
Patient-reported outcome measures should not be the primary outcome in glaucoma clinical trials of disease modification
Publication history
- Received November 2, 2021
- Accepted June 21, 2022
- First published July 5, 2022.
Online issue publication
December 15, 2022
Article Versions
- Previous version (15 December 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.